0

Ultralong Circulating Choline Phosphate Liposomal Nanomedicines for Cascaded Chemo-Radiotherapy

Xiaoqiu Li, Yangyang Zhao, Wei Jiang, Shuya Li, Meixiao Zhan, Hao Liu, Congjun Zhang, Hui Liang, Hang Liu, Ligong Lu, Yucai Wang

Biomater Sci. 2019 Mar 26;7(4):1335-1344.

PMID: 30816393

Abstract:

Cancer radiation therapy (RT) is limited by endogenous DNA repair of tumor cells and microenvironmental hypoxia in tumor tissues. Herein, we demonstrated an effective cancer chemo-radiotherapy strategy based on choline phosphate liposomal nanomedicines, which inhibit the intrinsic radioresistance of RT and concomitantly harness the RT-induced hypoxia to produce additional toxicity to overcome post-RT radioresistance. To achieve this strategy, a radiotherapy sensitizer, vorinostat, and a hypoxia-activated banoxantrone dihydrochloride (AQ4N) were simultaneously delivered to a tumor using liposomes composed of an inverted polarity lipid 2-((2,3-bis(oleoyloxy)propyl)dimethylammonio)ethyl ethyl phosphate (DOCPe). The DOCPe liposomes exhibited a longer blood circulation time and enhanced tumor accumulation, compared to their zwitterionic phosphocholine counterpart. The RT was sensitized by vorinostat to kill non-tolerant normoxic tumor cells efficiently. The irradiation aggravated hypoxia-activated AQ4N to further potentiate RT treatment. This chemo-radiotherapy combination showed excellent tumor treatment efficacy and is promising for future clinical translation.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP252979569 Banoxantrone dihydrochloride Banoxantrone dihydrochloride 252979-56-9 Price
qrcode